quinta-feira, 22 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 14, 2026

Stocks Rally on a Push for Diplomacy to End US-Iran War

View original at nasdaq.com
Stocks Rally on a Push for Diplomacy to End US-Iran War The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.66%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.81%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Would target all ports in and close to Persian Gulf if its own shipping hubs are threatened

    60% confidence
  • Talks with Iran could resume over the next two days in Pakistan

    60% confidence
  • Eurozone economy is between the baseline and adverse projections in ECB's base case, reflecting the war in Iran

    60% confidence
  • Q1 S&P 500 earnings projected to climb +12% year-over-year

    60% confidence
  • Denied report that it was seeking to acquire Dell Technologies or HP Inc

    60% confidence
  • Floated a possible combination with American Airlines

    60% confidence
  • Stripping out technology sector, Q1 earnings projected to increase around 3%, the weakest in two years

    60% confidence
  • Will not vote in favor of Kevin Warsh until Trump administration drops threat to prosecute Fed Chair Powell for cost overruns on Fed building

    60% confidence
  • Optimistic that Trump administration will soon drop investigation into Fed Chair Powell

    60% confidence
  • Faster inflation due to Iran war doesn't make an interest rate hike self-evident

    60% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,426 documentos-fonte arquivados
Consulte estes dados → isubstrate.com